{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:46:30Z","timestamp":1779205590108,"version":"3.51.4"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T00:00:00Z","timestamp":1126569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Fludarabine plus cytarabine (Ara\u2010C) and idarubicin (FLAI) is an effective and well\u2010tolerated induction regimen for the treatment of acute myeloid leukaemia (AML). This phase III trial compared the efficacy and toxicity of FLAI <jats:italic>versus<\/jats:italic> idarubicin plus Ara\u2010C and etoposide (ICE) in 112 newly diagnosed AML patients &lt;60\u2003years. Fifty\u2010seven patients received FLAI, as the first induction\u2013remission course, and 55 patients received ICE. Post\u2010induction treatment consisted of high\u2010dose Ara\u2010C (HDAC). After HDAC, patients in complete remission (CR) received a second consolidation course (mitoxantrone, etoposide, Ara\u2010C) and autologous stem cell transplantation (auto\u2010SCT) or allogeneic (allo)\u2010SCT, according to the age, disease risk and donor availability. After a single induction course, CR rate was 74% in the FLAI arm and 51% in the ICE arm (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b701), while death during induction was 2% and 9% respectively. Both haematological (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7002) and non\u2010haematological (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b70001) toxicities, especially gastrointestinal (i.e. nausea, vomiting, mucositis and diarrhoea), were significantly lower in FLAI arm. In both arms, relapses were more frequent in patients who were not submitted to allo\u2010SCT. After a median follow\u2010up of 17\u2003months, 30% and 38% of the patients are in continuous CR in FLAI and ICE arm respectively. Our prospective randomised study confirmed the anti\u2010leukaemic effect and the low toxic profile of FLAI as induction treatment for newly diagnosed AML patients.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05745.x","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T15:34:41Z","timestamp":1126625681000},"page":"172-179","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Multicentre phase III trial on fludarabine, cytarabine (Ara\u2010C), and idarubicin <i>versus<\/i> idarubicin, Ara\u2010C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients"],"prefix":"10.1111","volume":"131","author":[{"given":"Domenico","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Malagola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"de Vivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Fiacchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier P.","family":"Piccaluga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Michielutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Testoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Rondoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarla","family":"Pricolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizio","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana","family":"Zuffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Zaccaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Raspadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Lauria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Avanzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Visani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,9,30]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"239","volume-title":"The European Group for Blood and Marrow Transplantation (EBMT) Handbook","author":"Apperley J.","year":"2004"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"e_1_2_6_4_1","first-page":"115","article-title":"Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute non lymphocytitc leukemia: results of the L\u201016M protocol","volume":"3","author":"Berman E.","year":"1989","journal-title":"Leukemia"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1373\/49.10.1642"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V75.1.27.27","article-title":"Etoposide in acute non lymphocytic leukemia","volume":"75","author":"Bishop J.F.","year":"1990","journal-title":"Blood"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971201)80:11 <2191::AID-CNCR5>3.0.CO;2-L"},{"key":"e_1_2_6_8_1","first-page":"4116","article-title":"Double induction strategy for acute myeloid leukemia: the effect of high dose cytarabine with mitoxantrone instead of standard dose cytarabine with daunorubicin and 6\u2010thioguanin: a randomized trial by the German AML Cooperative Group","volume":"93","author":"Buchner T.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02178.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392301"},{"key":"e_1_2_6_11_1","first-page":"481","article-title":"Fludarabine, ARA\u2010C, idarubicin and G\u2010CSF (FLAG\u2010Ida), high dose ARA\u2010C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients","volume":"21","author":"Clavio M.","year":"2002","journal-title":"Journal of Experimental Clinical Cancer Research"},{"key":"e_1_2_6_12_1","first-page":"290","article-title":"P\u2010glycoprotein (PGP) and not lung resitance\u2010related protein (LRP) is a negative prognostic factor in secondary leukemias","volume":"83","author":"Damiani D.","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_6_13_1","first-page":"503","article-title":"The type of anthracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC\u2010GIMEMA AML\u201010 randomized trial","volume":"96","author":"De Witte T.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309148532"},{"key":"e_1_2_6_15_1","first-page":"1687","article-title":"HLA identical sibling bone marrow transplant vs chemotherapy for acute myeloid leukemia in first remission","volume":"10","author":"Gale R.P.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.08.013"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1302"},{"key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial","volume":"7","author":"Grimwade D.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1312"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood.V89.7.2311","article-title":"Randomized comparison of DAT vs ADE as induction chemotherapy in children and young adults with acute myeloid leukaemia. Results of the Medical Research Council's 10th AML trials (AML MRC 10)","volume":"89","author":"Hann I.M.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_21_1","volume-title":"Leukemia","author":"Henderson E.S.","year":"2002"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200392"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_24_1","first-page":"1015","article-title":"Therapy of acute myeloid leukemia: towards a patient\u2010oriented, risk adapted approach","volume":"83","author":"Mandelli F.","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_6_25_1","first-page":"143","article-title":"Effect of fludarabine and arabinosyl cytosine on multidrug resistant cells","volume":"82","author":"Michelutti A.","year":"1997","journal-title":"Haematologica"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309147379"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01172.x"},{"key":"e_1_2_6_28_1","volume-title":"ISCN: An International System for Human Cytogenetic Nomenclature","author":"Mitelman F.","year":"1995"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2195"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1769.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.V90.6.2121","article-title":"Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged","volume":"90","author":"Rowe J.M.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00003-6"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109057932"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3714"},{"key":"e_1_2_6_35_1","first-page":"2076","article-title":"Fludarabine\u2003+\u2003AraC\u2003+\u2003G\u2010CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells","volume":"8","author":"Tosi P.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11239"},{"key":"e_1_2_6_37_1","first-page":"1842","article-title":"FLAG (fludarabine\u2003+\u2003high dose AraC\u2003+\u2003G\u2010CSF): an effective and tolerable protocol for the treatment of poor risk acute myeloid leukemias","volume":"8","author":"Visani G.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01379.x"},{"key":"e_1_2_6_39_1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","article-title":"A phase III trial comparing idarubicine and daunorubicin in combination with cytarabine in AML: a Southeastern Cancer Study Group","volume":"16","author":"Vogler W.R.","year":"1992","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501263320403"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05745.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05745.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:17:04Z","timestamp":1697419024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05745.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,30]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05745.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05745.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,30]]},"assertion":[{"value":"2005-09-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}